Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Cambridge, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- If you’re considering setting a goal to lose weight in 2026, there is good news: Generative artificial intelligence can help. MIT Sloan School of...
-
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk’s newly...
-
Industry analysis compares FDA-approved Wegovy pricing from $149 oral to Ro's $199 injectable as telehealth access expands for 2026.
-
Industry analysis examines herbal wellness patch ingredients and regulatory classification as GLP-1 alternative searches surge heading into 2026.
-
Industry analysis examines herbal wellness patch ingredients and regulatory classification as GLP-1 alternative searches surge heading into 2026.
-
Analysis examines Direct Meds GLP-1 medications platform as LegitScript-certified telehealth option for compounded semaglutide and tirzepatide access.
-
Independent analysis of best weight loss patches and GLP-1 patch products as FDA approves once-daily Wegovy pill for chronic weight management.
-
SkinnyRx offers compounded semaglutide in 3 forms starting at $199/month through licensed providers as New Year weight loss demand approaches.
-
NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...